Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model

By
Laurisa Dohm
-
0
207
The prodrug tested demonstrated a dose-dependent effect to reduce the tumor volume of 22Rv1 prostate cancer xenografts without observed toxicity.
[Journal Of Medicinal Chemistry]
AbstractGraphical Abstract